



Ask Your Representatives to Support the PIE Act

The PIE Act of 2022 ([H.R. 7008](#)) is one of AMCP's top federal priorities. This important bipartisan bill will enhance patient access to emerging pharmaceuticals and devices by authorizing pharmaceutical manufacturers to proactively share certain health care economic and scientific information about products with health payers ahead of Food & Drug Administration (FDA) approval. Although the FDA finalized guidance in 2018 regarding PIE, confusion remains around the circumstances under which manufacturers can provide information prior to approval and the nature of the information that can be provided. The PIE Act of 2022 will clarify the scope of PIE and resolve inconsistencies between the guidance and relevant statutory law. Learn more by reading our [issue brief](#).

Visit our [Action Center](#) to urge Congress to pass the PIE Act of 2022.

Discover an MS DMT with **2 years of**
real-world adherence and persistence data

[See the Full Study](#)

Eye On Washington

AMCP Legislative Agenda 2022 and Beyond Webinar – Thursday, April 7

On April 7, AMCP's Policy & Government Relations staff will present AMCP's policy and government relations agenda in a members-only webinar. The webinar will provide an overview of the department's strategy to achieve success on four primary/lead issues: the PIE Act of 2022, creating a Medicare benefit category for prescription digital therapeutics, establishing a federal Biosimilars Research Fund, and promoting AMCP's Pharmacy Pay for Performance Principles.

Register for the [webinar](#).

AMCP Signals Support for Legislative Priorities

On March 3, AMCP responded to a Request for Information (RFI) on digital technologies in health care from the House Republican Healthy Futures Task Force Subcommittee on Modernization. AMCP used the RFI to support legislative and regulatory solutions to remove barriers to coverage and payment for Digital Therapeutics in the Medicare program. On March 11, AMCP submitted comments in response to an RFI from the Healthy Futures Task Force regarding research and access to innovative new drugs and devices. AMCP reiterated its support for the Pre-approval Information Exchange Act, the creation of a benefit category for digital therapeutics, and improved collection of real-world evidence and confirmatory data for accelerated approval drugs.

Read AMCP's [response](#).

Advocacy Tip

Stay up-to-date: Read AMCP's [Letters, Statements and Analysis](#) on all legislation and regulation impacting managed care pharmacy.

AMCP Supports Authorization for Pharmacists to Order COVID-19 Antivirals

On March 9, AMCP joined 13 pharmacy organizations, expressing our concern that FDA's exclusion of pharmacists from the Emergency Use Authorization (EUA) for COVID-19 oral antivirals will undermine the intent and efficacy of the test to treat initiative. The letter calls on the Administration to take immediate action to remove the EUA limitations and ensure the broadest possible access to oral antivirals for all Americans.

Read the [letter](#).

AMCP Responds to Part D Proposed Rule

On March 7, AMCP submitted comments on CMS's proposal to redefine negotiated price as the lowest possible payment that a Part D plan will make to a pharmacy. The proposal would require all pharmacy price concessions to be reflected at the point-of-sale but does not cover manufacturer rebates. AMCP expressed concerns that this proposal would increase costs for Part D beneficiaries, plan sponsors, and taxpayers. AMCP urged CMS to reconsider the proposal so that it could continue to study the use of pharmacy performance measurements and performance-based payments.

Read AMCP's [comment letter](#).

AMCP is a Healthy People 2030 Champion

After HHS released the Healthy People 2030 framework in 2020, the Office of Disease Prevention and Health Promotion (ODPHP) invited organizations that support the Healthy People program's vision to become Champions. AMCP highlighted our members' commitment to increase access to quality health care, address health care disparities, and promote innovative technologies that can improve care delivery. AMCP was accepted as a Healthy People Champion in February 2022.

Discover
an MS DMT
with **2 years**
of real-world
adherence
and
persistence
data

See the
Full Study

AMCP

675 North Washington Street, Suite 220, Alexandria, VA 22314
703.684.2600 | www.amcp.org

[Manage My Emails](#)